

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

Drug Requested: **Revlimid® (lenalidomide)**

DRUG INFORMATION: Complete below. Incomplete information will delay authorization process.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

CLINICAL CRITERIA: Check applicable box (es) below. If **not** checked, authorization process will be delayed.

- Prescriber is registered in the **REVLIMID REMS®** program.

AND

- Patient is being treated for transfusion-dependent anemia due to Low-or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

OR

- Patient is being treated for multiple myeloma, in combination with dexamethasone

OR

- Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Medication being provided by (check applicable box below):

- Physician's office

OR

- Specialty Pharmacy:

- Briova SpecialtyRx

****Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone #: _____ Fax #: _____

DEA OR NPI #: _____

*Approved by the Pharmacy Therapeutics Committee: 3/16/2006

REVISED/UPDATED: 6/3/2011; 9/7/2011; 8/13/2014; 11/5/2014; 5/12/15; 5/22/2015; 8/11/2015; 12/29/2015; 9/22/2016; 12/11/2016; 5/5/2017; 9/27/2017; 10/7/2017.